TY - JOUR AU - Hassanipour, Soheil AU - Vali, Mouhebat AU - Gaffari-fam, Saber AU - Nikbakht, Hossein-Ali AU - Abdzadeh, Elham AU - Joukar, Farahnaz AU - Pourshams, Akram AU - Shafaghi, Afshin AU - Malakoutikhah, Mahdi AU - Arab-Zozani, Morteza AU - Salehiniya, Hamid AU - Mansour-Ghanaei, Fariborz PY - 2020/01/13 Y2 - 2024/03/29 TI - The survival rate of hepatocellular carcinoma in Asian countries: a systematic review and meta-analysis JF - EXCLI Journal JA - EXCLI J. VL - 19 IS - 0 SE - Review articles DO - 10.17179/excli2019-1842 UR - https://www.excli.de/index.php/excli/article/view/1599 SP - 108-130 AB - <p class="Abstract"><span lang="EN-US">Hepatocellular carcinoma or Liver cancer (LC) is the sixth most common cancer and the fourth cause of death worldwide in 2018. There has not been a comprehensive study on the survival rate of patients with LC in Asia yet. Therefore, the present study was conducted to evaluate the survival rate of patients with LC in Asian countries. The methodology of the present study is based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement. The researchers searched five international databases including Medline/PubMed, Scopus, Embase, Web of Knowledge and ProQuest until July 1, 2018. We also searched Google Scholar for detecting grey literature. The Newcastle-Ottawa Quality Assessment Form was used to evaluate the quality of selected papers. A total of 1425 titles were retrieved. 63 studies met the inclusion criteria. Based on the random-effect model one-year, three-year and five-year survival rate of LC were 34.8&nbsp;% (95&nbsp;% CI; 30.3-39.3), 19&nbsp;% (95&nbsp;% CI ; 18.2-21.8) and 18.1&nbsp;% (95&nbsp;% CI ;16.1-20.1) respectively. According to the results of our study, the LC survival rate in Asian countries is relatively lower than in Europe and North America.</span></p> ER -